OSA-related arousal burden could raise the dose needed for any sleep-mediated neuroprotective effect, perhaps toward 100 mg rather than 50 mg. This is the least supported development hypothesis because it depends on a long causal chain from OSA physiology to biomarker benefit in dementia and is heavily confounded by standard OSA care and endotype heterogeneity.
Curated pathway from expert analysis
flowchart TD
A["Obstructive Sleep Apnea<br/>Nocturnal Arousal Burden"]
B["HTR2A Signaling<br/>Serotonin Receptor 2A"]
C["HRH1 Histamine Receptor<br/>Mediator Release"]
D["Sleep Architecture<br/>Disruption"]
E["Higher Trazodone<br/>Dose Requirement"]
F["REM Suppression<br/>Sleep Quality Impact"]
G["Precision Dosing<br/>via HTR2A/HRH1 Stratification"]
A --> B
A --> C
B --> D
C --> D
D --> E
E --> F
G -.->|"optimizes"| E
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for HTR2A; yet. Search RCSB →
Median TPM across 13 brain regions for HTR2A; HRH1 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HTR2A; HRH1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF older adults with high nocturnal arousal burden (>15 arousals/hour on polysomnography) receive 100 mg trazodone versus 50 mg trazodone for 12 weeks, THEN the high-dose group will show superior impr | Sleep efficiency increases by ≥8% in high-dose group; CSF NfL decreases by ≥15% relative to low-dose group within 3 months | — no observation — | pending | 0.25 |
| IF OSA status is added as a stratification variable to a cohort receiving trazodone 50 mg nightly for 8 weeks, THEN patients without OSA will exhibit significantly greater improvement in next-morning | Non-OSA group shows ≥20% greater improvement in DSST scores compared to OSA group at 8 weeks | — no observation — | pending | 0.20 |